- Home
- CPBI vs AARD Comparison
CPBI vs AARD Comparison
Compare CPBI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | AARD |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 97.4M |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CPBI | AARD |
|---|---|---|
| Price | $20.75 | $1.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 3.5K | ★ 1.1M |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.38 | ★ 43.11 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $52.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.56 | $0.93 |
| 52 Week High | $21.83 | $16.60 |
Technical Indicators
Market Signals| Indicator | CPBI | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 24.84 |
| Support Level | $19.74 | N/A |
| Resistance Level | $21.67 | $5.88 |
| Average True Range (ATR) | 0.29 | 0.49 |
| MACD | 0.10 | -0.26 |
| Stochastic Oscillator | 87.18 | 12.92 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans. The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans. The company's revenue is derived from the business of banking.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.